Cue Biopharma (CUE) Enterprise Value (2017 - 2025)

Cue Biopharma has disclosed Enterprise Value across 9 years of filings, most recently posting -$27.7 million for Q4 2025.

• Enterprise Value for Q4 2025 came in at -$27.7 million, down 18.41% year-over-year; the trailing twelve-month figure through Dec 2025 was -$27.7 million (down 18.41% YoY), and the FY2025 annual result was -$27.7 million, down 18.41% from the prior year.
• Enterprise Value came in at -$27.7 million for Q4 2025 at Cue Biopharma, down from -$18.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$14.0 million in Q1 2025 to a low of -$76.3 million in Q4 2022.
• The 5-year median for Enterprise Value is -$53.4 million (2021), against an average of -$48.9 million.
• Across the five-year window, Enterprise Value slumped 50.33% in 2021 and surged 65.76% in 2025, its largest moves.
• Cue Biopharma's Enterprise Value stood at -$52.2 million in 2021, then tumbled by 46.12% to -$76.3 million in 2022, then soared by 36.03% to -$48.8 million in 2023, then soared by 52.07% to -$23.4 million in 2024, then slipped by 18.41% to -$27.7 million in 2025.
• The last three Enterprise Value figures came in at -$27.7 million (Q4 2025), -$18.2 million (Q3 2025), and -$28.0 million (Q2 2025), per Business Quant data.